![Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F63025.jpg&w=3840&q=50)
口服托芬在健康人群中激活十二指甲基化合物受体:一个交叉随机对照试验
Gaston H Rueda1, Natalia Causada-Calo1, Rajka Borojevic1
1Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
概括
在健康成年人中,口服托芬补充剂激活了小肠道,促进了酸受体 (AhR) 激活和免疫调节代谢物. 这支了托芬的支持.
科学领域:
- 营养免疫学 营养免疫学
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
背景情况:
- 托芬代谢物通过烯碳水化合物受体 (AhR) 激活来调节粘膜平衡.
- 托代谢的改变与慢性炎症有关.
- 托补充剂对人类代谢物概况和AhR激活的影响在很大程度上是未知的.
研究的目的:
- 调查口服l-三补充剂对健康人群代谢物库和AhR激活的影响.
- 评估胃肠道/心理症状的变化,AhR激活,托代谢物,细胞因子的产生和微生物群的形状.
主要方法:
- 这是一项随机,双盲,安慰剂控制,交叉研究,对20名健康志愿者进行了低托饮食.
- 3周的干预期为l-三 (3g/天) 或安慰剂,随后是2周的洗和切换干预期.
- 评估包括验证的问卷,AhR激活测定,代谢物的液体染色体质谱,细胞因子的ELISA和微生物群的16SrRNA测序.
主要成果:
- 口服托补充剂被很好地容忍,胃肠道或心理症状没有显著变化.
- 托芬增加了十二指甲状腺含量中的AhR激活能力,并与更高的尿/血 kynurenine 和英多尔代谢产物并行.
- 观察到对便微生物群的适度影响,对细胞因子产生没有显著影响.
结论:
- 在人类中,口服托补充剂会诱导微生物的道和小肠中的宿主 kynurenine 途径,这已知具有免疫调节作用.
- 这些发现表明,托补充剂可以激活免疫调节的AhR通路和小肠中的内代谢.
- 结果支持用于小肠炎症状况的托芬干预策略,其中AhR通路受损.
更多相关视频
10:38Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
Published on: May 9, 2020
3.4K
07:05Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
8.9K
相关概念视频
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
249
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
249
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K